Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: GERD in Infants Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

NCT00992589
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
1 Month to 11 Months
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Columbiana, Alabama • Dothan, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Jul 22, 2026, 4:52 PM EDT
Recruiting Not applicable Interventional

Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia

NCT06534359
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Gastroesophageal Reflux
Interventions
Transpyloric tube feeding, Gastric tube feeding
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 12 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional

The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux

NCT00324974
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Lansoprazole microgranules suspension, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Month to 11 Months
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Tampa, Florida • Park Ridge, Illinois • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2010 · Synced Jul 22, 2026, 4:52 PM EDT
Recruiting No phase listed Observational

A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

NCT06660342
View directory record Official record
Conditions
Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

NCT00855361
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Up to 44 Weeks
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Orange, California • Washington D.C., District of Columbia • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)

NCT00373334
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, GERD, Heartburn
Interventions
nizatidine (axid), placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
30 Days to 1 Year
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Hot Springs, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2009 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD

NCT00259012
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole sodium enteric-coated spheroid suspension
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Month to 11 Months
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
16
States / cities
Little Rock, Arkansas • Loma Linda, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 6, 2010 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Phase 1 Interventional

Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants

NCT00744419
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole
Drug
Lead sponsor
University of Louisville
Other
Eligibility
28 Weeks to 11 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Jul 22, 2026, 4:52 PM EDT
Recruiting Not applicable Interventional

GERD Infant Feeding Therapeutics Trial (GIFT Trial)

NCT06114836
View directory record Official record
Conditions
GERD in Infants
Interventions
Omeprazole, AR formula
Drug · Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Day to 8 Months
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 22, 2026, 4:52 PM EDT
Withdrawn Phase 1 Interventional

Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months

NCT02442752
View directory record Official record
Conditions
Pediatric Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Month to 11 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Los Angeles, California • Louisville, Kentucky • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Jul 22, 2026, 4:52 PM EDT
Withdrawn Not applicable Interventional

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

NCT02700087
View directory record Official record
Conditions
Laryngomalacia, Acid Reflux, Stridor
Interventions
ranitidine or famotidine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 4 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Phase 3/Safety & Efficacy of Esomeprazole in Infants

NCT00468559
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Month to 11 Months
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)

NCT00868296
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Day to 12 Months
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
45
States / cities
Phoenix, Arizona • Loma Linda, California • Oakland, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Not applicable Interventional Results available

Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial

NCT02486263
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Study Arm - acid suppression plus feeding bundle, Conventional arm - acid suppression only
Other
Lead sponsor
Sudarshan Jadcherla
Other
Eligibility
34 Weeks to 60 Weeks
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants

NCT00131248
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Metaclopramide, Ranitidine, placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Month to 6 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT00365300
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
28 Days to 11 Months
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Phase 4 Interventional

The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia

NCT00926276
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Bronchopulmonary Dysplasia
Interventions
Fundoplication
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
24 Weeks to 1 Year
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Jul 22, 2026, 4:52 PM EDT
Recruiting Not applicable Interventional

Randomized Controlled Crossover Trial of Postpyloric Feedings to Improve Pulmonary Outcomes in High-risk Preterm Infants

NCT05777512
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Gastric Feeds, Jejunal Feeds
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Hours to 1 Year
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD

NCT00362609
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Day to 28 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Phoenix, Arizona • Loma Linda, California • Oakland, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Jul 22, 2026, 4:52 PM EDT